Mr. Agarwal joined Ultragenyx as Chief Medical Officer in August 2014.
Prior to Ultragenyx, he served in various leadership capacities at Genentech for 11 years. Most recently he held the position of Senior Vice President and Global Head of Clinical Development for OMNI (Ophthalmology, Metabolism, Neurosciences, Immunology and Infectious Diseases) since January 2013.
Prior to that, Mr. Agarwal held the positions of Senior VP for Immunology and Infectious Diseases, and VP for Rheumatology from July 2009 to December 2012.
He also held the position of VP of Genentech Drug Safety from January 2009 to July 2009. From September 2003 to January 2009, he held positions of increasing responsibility in Genentech’s Immunology clinical organization.
Before joining Genentech, Mr. Agarwal was at MedImmune and Guilford Pharmaceuticals where he worked in both development and medical affairs and led the formation of the medical affairs organization for Guilford.
Mr. Agarwal obtained his Bachelor of Science in Neuro-Biology at Cornell University and then earned his medical degree from Tufts University School of Medicine.
Mr. Agarwal completed his residency at Children’s National Medical Center (CNMC), Washington, D.C. and subsequently joined the facility at George Washington University School of Medicine as an Assistant Clinical Professor of Pediatrics. He practiced in the Pediatric Emergency Department at CNMC. ■
LATEST MOVES FROM California
- ChromaDex appoints Steven Rubin to board
- Impax Laboratories appoints Paul M. Bisaro as CEO
- Retrophin names John A. Orwin to board
- Intel appoints two to board
- Walt Disney Company extends CEO's contract to 2019
More inside POST